AKR1C pan-inhibitor overcomes drug resistance in breast cancer models
April 24, 2025
Acquired resistance to doxorubicin significantly reduces its therapeutic efficacy, limiting its clinical use in breast cancer treatment. Pan-AKR1C inhibitors have demonstrated potential in restoring drug sensitivity in resistant cancer cells.